We are almost there ...
Natco just can’t kick its high-risk, high-gain game plan
CEO Rajeev Nannapaneni’s oft-used strategy of mounting patent challenges in the US got the pharma company its latest blockbuster Revlimid. But what after sales fall off a cliff?
03 October, 2024•12 min
0
03 October, 2024•12 min
0
Subscribe to read this story
We publish over 500 original, detailed stories every year on startups, corporates, stock markets and economic current affairs.
Limited time offer $125 $99 for 1 year
SUBSCRIBE
Already have an account? Sign In
More in Business
Business
This company makes India’s best-selling electric motorcycles (and it’s not Ola)
Delhi-based Revolt Motors has emerged as a standout story for electric motorcycles in India against all odds. Now it has to prepare for an onslaught of new competition, starting with top e-scooter maker Ola.
You may also like
Internet
Why is Swiggy catching flak for its latest quick-delivery promise?
The food and grocery delivery company’s idea of providing prescription drugs in 10 minutes is facing resistance from traditional pharma players.
Business
KKR set to hit the jackpot with JB Chemicals and Pharma
The investment giant is rumoured to be eyeing an exit with a 5x return, having taken the drugmaker from obscurity to a billion-dollar bidding war.
Business
For Sun Pharma’s Dilip Shanghvi, specialty drugs remain the magic bullet
Specialty drugs are fast becoming a lucrative market globally. And India’s largest drugmaker has done well to make the most of this opportunity so far. But it’s too soon to rest easy.